Solid lipid nanoparticles system: An overview

International Journal of Research in Pharmaceutical Sciences

Volumn 2, Issue 3, 2011, Pages 450-461

  Sharma, Vijay Kumar ^a   Diwan, Anupama ^a   Sardana, Satish ^a   Dhall, Vipan ^b  

^a Hindu College   (India)

^b Piramal Enterprises Limited   (India)

Author keywords

Colloidal carrier; Hot homogenization; Solid lipid nanoparticles

Indexed keywords

ACYLGLYCEROL; ALCOHOL; BILE SALT; CAMPTOTHECIN; CISPLATIN; DIAZEPAM; DOXORUBICIN; ETHYLENE OXIDE; ETOPOSIDE; FATTY ACID; IDARUBICIN; MEVINOLIN; MICONAZOLE NITRATE; MIFEPRISTONE; PACLITAXEL; PHOSPHOLIPID; PODOPHYLLOTOXIN; RETINOL; SOLID LIPID NANOPARTICLE; STEROID; SURFACTANT; TOBRAMYCIN; TRIACYLGLYCEROL; WAX;

ANEMOMETRY; ARTICLE; ATOMIC FORCE MICROSCOPY; BIOASSAY; BIODEGRADABILITY; BLOOD BRAIN BARRIER; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG ACCUMULATION; DRUG ANTIGENICITY; DRUG BIOAVAILABILITY; DRUG DIFFUSION; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG TARGETING; FLOCCULATION; FREEZE DRYING; HYDROPHOBICITY; MASS SPECTROMETRY; MICROEMULSION; NONHUMAN; PARTICLE SIZE; PHASE SEPARATION; PHOTON CORRELATION SPECTROSCOPY; POTENTIOMETRY; SCANNING ELECTRON MICROSCOPY; SHEAR STRESS; TRANSMISSION ELECTRON MICROSCOPY; ULTRACENTRIFUGATION; X RAY PHOTOELECTRON SPECTROSCOPY; ZETA POTENTIAL;

EID: 79960947321     PISSN: None     EISSN: 09757538     Source Type: Journal    
DOI: None     Document Type: Article

References (102)

1. Abdelbary G and Fanmy RH. (2009) Diazepam-loaded solid lipid nanoparticles:design and characterization. AAPS PharmSciTech 10: 211-219.
2. Ahlin P. (1998) Optimization of procedure parameters and physical stability of solid lipid nanoparticles in dispersions. Acta Pharm 48: 257-267.
3. Ammoury N, Fessi H, Devissaguet JP, et al. (1990) In-vitro release pattern of indomethacin from poly (DL lactide) nanocapsules. J Pharm Sci 79: 763-767.
4. Amselem S, Cohen R and Barenholz Y. (1993) In-vitro test to predict the in-vivo performance of liposomal dosage form. Chem. Phys. Lipids 64: 219-237.
5. Bargoni A, Cavalli R, Zara GP, et al. (2001) Transmuco-sal transport of tobramycin incorporated in solid lipid nanoparticles (SLN) after duodenal administration to rats. Part II-Tissue distridution. Pharmacol Res 43: 497-502.
6. Bhalekar MR, Pokharkar V, Madgulkar A, et al. (2009) Preparation and evaluation of miconazole nitrate loaded solid lipid nanoparticles for topical delivery AAPS PharmSciTech 10: 289-296.
7. Bocca C, Caputo O, R.Cavalli, et al. (1998) Phagocytic uptake of fluorescent stealth and non-stealth solid lipid nanoparticles. Int J Pharm 175: 176-184.
8. Brasseur N, D.Brault and Couvreur P. (1991) Adsorption of hematoporphyrin onto polyalkylcyanoacrylate nanoparticles: carrier capacity and drug release. Int J Pharm 70: 129-135.
9. Bunjes H. (2005) Characterization of solid lipid nanoparticles. Lipospheres Drug Targets Delivery: 41-67.
10. Cappel MJ and Kreuter J. (1991) Effect of nanoparticles on transdermal drug delivery. J Microencapsul 8: 389-401.
11. Carr JME, Powers PL and Jones MR. (1991) Effect of poloxamer 188 on the assembly, structure and disso-lution of fibrin clots. Thromb Haemost 66: 565-568.
12. Casadei MA, Cerreto F, Cesa S, et al. (2006) Solid lipid nanoparticles incorporated in dextran hydrogels: A new drug delivery system for oral formulations. Int J Pharm 325: 140-146.
13. Cavalli R. (1998) The effect of components of microe-mulsions on both size and crystalline structure of solid lipid nanoparticles (SLN) containing a number of model molecules. Pharmazie 53: 392-396.
14. Cavalli R, Bergoni A, Podio V, et al. (2003) Duodenal administration of solid lipid nanoparticles loaded with different percent of tobramycin. J Pharm Sci 92: 1085-1094.
15. Cavalli R, Caputo O and Gasco MR. (2000) Preparation and Characterization of solid lipid nanospheres con-taining paclitaxel. Eur J Pharm Sci 10: 305-309.
16. Cavalli R, Gasco MR, Chetoni P, et al. (2002) Solid lipid nanoparticles (SLN) as ocular delivery system for to-bramycin. Int J Pharm 238: 241-245.
17. Chen H, Chang X, Du D, et al. (2006) Podophyllotoxin-loaded solid lipid nanoparticles for epidermal target-ing. J Control Release 110: 296-306.
18. Doijad RC, Manvi FV, Godhwani DM, et al. (2008) For-mulation and Targeting efficiency of cisplatin engi-neered solid lipid nanoparticles. Indian J Pharm Sci 70: 203-207.
19. Douglas SJ, Davis SS and Illum L. (1987) Nanoparticles in drug delivery. CRC Crit Rev Ther. Drug Carr. Syst 3: 233-261.
20. Dubes A, Parrot-Lopez H, Abdelwahed W, et al. (2003) Scanning electron microscopy and atomic force imag-ing of solid lipid nanoparticles derived from amphi-philic cyclodextrins. Eur J Pharm Biopharm 55: 279-282.
21. Eldem T, Speiser P and Hincal A. (1991) Optimization of spray dried and congealed lipid micropellets and characterization of their surface morphology by scanning electron microscopy. Pharm Res 8: 47-54.
22. Flanagan J and Singh H. (2006) Microemulsions: A po-tential delivery system for bioactives in food. Crit Rev Food Sci Nutri 46: 221-237.
23. Freitas C and Muller RH. (1998) Spray drying of solid lipid nanoparticles (SLN). Eur J Pharm Biopharm 46: 145-151.
24. Fundaro A, Cavalli R, Bergoni A, et al. (2000) Non-stealth and stealth solid lipid nanoparticles carrying doxorubicin: Pharmacokinetic and tissue distribution after i.v administration to rats. Pharmacol Res 42: 337-343.
25. Gasco MR and Antonelli LP. (1993) Method for prepar-ing solid lipid microspheres having a narrow size dis-tribution. In: patent U (ed).
26. Gohla SH and Dingler A. (2001) Scaling up feasibility of the production of solid lipid nanoparticles (SLNTM). Pharmazie 56: 61-63.
27. Gref R, Minamitake Y, Peracchia MT, et al. (1994) Bio-degradable long circulating polymeric nanospheres. Science 263: 1600-1603.
28. Gregoriadis G. (1998) Targeting of Drugs: strategies for stealth therapeutic systems, New York: Pienum Press.
29. Heiati H, Tawashi R and Phillips NC. (1998) Drug reten-tion and stability of solid lipid nanoparticles contain-ing azidothymidine palmitate after autoclav-ing,storage and liophilization. J Microencapsul 15: 173-184.
30. Hermina T, Kreuter J, Speiser P, et al. (1986) Enhance-ment of myotic response of rabbit with pilocarpine loaded polybutylcyanoacrylate nanoparticles. Int J Pharm 33: 187-198.
31. Hong Y, Hu FQ and Yang H. (2006) Effect of PEG2000 on drug delivery characterization from solid lipid nanoparticles. Pharmazie 61: 312-315.
32. Hou DZ, Xie CS, Huang K, et al. (2003) The production and characteristics of solid lipid nanoparticles (SLNs). Biomaterials 24: 1781-1785.
33. Hu FQ, Yuan H, Zhang HH, et al. (2002) Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous sys-tem and physicochemical characterization. Int J Pharm 239: 121-128.
34. Iscan Y, Hekimoglu S, Sargon MF, et al. (2006) DEET-loaded solid lipid particles for skin delivery: In vitro release and skin permeation characteristics in differ-ent vehicles. J Microencapsul 23: 315-327.
35. Jores K, Mehnert W, Drechsler M, et al. (2004) Investi-gations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by pho-ton correlation spectroscopy, field-flow fractionation and transmission electron microscopy. J Control Re-lease 95: 217-227.
36. Kalariya M, Padhi BK, Chougule M, et al. (2005) Clobe-tasol propionate solid lipid nanoparticles creams for effective treatment of eczema: Formulation and clini-cal implications. Indian J Exp Biol 43: 233-240.
37. Komatsu H, Kitajima A and Okada S. (1995) Pharmaceu-tical characterization of commercially available intra-venous fat emulsions: Estimation of average particle size, size distribution and surface potential using pho-ton correlation spectroscopy. Chem Pharm Bull 43: 1412-1415.
38. Koziara JM, Lockman PR, Allen DD, et al. (2003) In situ blood-brain barrier transport of nanoparticles. Pharm. Res 20: 1772-1778.
39. Koziara JM, Mumper RJ, Lockman PR, et al. (2004) Pa-clitaxel nanoparticles for the potential treatment of brain tumors. J Control Release 99: 259-269.
40. Koziara JM, Mumper RJ, Oh JJ, et al. (2005) Blood com-patibility of cetyl alcohol/polysorbate based nanopar-ticles. Pharm Res 22: 1821-1828.
41. Kreuter J. (1983) Evaluation of nanoparticles as drug delivery systems I. Preparation methods. Pharm. Acta Helv 58: 196-207.
42. Kreuter J. (1991) Nanopartilce-based drug delivery sys-tem. J Control Release 16: 169-179.
43. Levy MY and Benitas S. (1990) Drug release from sub-micron o/w emulsion: a new in-vitro kinetic evalua-tion model. Int J Pharm 66: 29-37.
44. Lim SJ and Kim CK. (2002) Formulation parameters de-termining the physiochemical characteristics of solid lipid nanoparticles loaded with all-trans retinoic acid. Int J Pharm 243: 135-146.
45. Liu J, Hu W, Chen H, et al. (2007) Isotretinoin-loaded solid lipid nanoparticles with skin targeting for topical delivery. Int J Pharm 328: 191-195.
46. Liu Y, Chu Y and Yang L. (2006) Adjusting the inner-structure of polypyrrole nanoparticles through mi-croemulsion polymerization. Mat Chem Phy 98: 304-308.
47. Lockman PR, Koziara J, Roder KE, et al. (2003) In vivo and in vitro assessment of baseline blood-brain bar-rier parameters in the presence of novel nanoparti-cles. Pharm. Res 20: 705-713.
48. Luo YF, Chen DW, Ren LX, et al. (2006) Solid lipid nanoparticles for enhanced vinpocetine's oral bioavailability. J Control Release 114: 53-59.
49. Magenheim B and Benita S. (1991) Nanoparticles char-acterization: a comprehensive physiochemical ap-proach. S.T.P. Pharm Sci 1: 221-241.
50. Magenheim B, Levy MY and Benita S. (1993) A new in Vitro technique for evaluation of drug release profile from colloidal carriers-ultrafiltration technique at low pressure. Int J Pharm 94: 115-123.
51. Malaiya A and Vyas SP. (1988) Preparation and charac-terization of magnetic nanoparticles. J Microencapsul 5: 243-254.
52. Manjunath K and Venkateshwarlu V. (2005) Pharma-cokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release 107: 215-228.
53. Mao S, Wang P and Bi D. (2005) Investigation on 5-fluorouracil solid lipid nanoparticles (SLN) prepared by hot homogenization. Pharmazie 60: 273-277.
54. Mehnert W and Mader K. (2001) Solid lipid nanoparti-cles: Production, characterization and applications. Adv Drug Deliv Rev 47: 165-196.
55. Minagawa T, Sakanaka K, Inaba SI, et al. (1996) Blood-brain-barrier transport of lipid microspheres contain-ing clinprost, a prostaglandin I2 analogue. J. Pharm. Pharmacol 48: 1016-1022.
56. Moulik SP and Paul BK. (1998) Structure, dynamics and transport properties of micro emulsions. Adv Colloid Interface Sci 78: 99-195.
57. Muller RH, Madar K and Gohla S. (2000) Solid lipid na-noarticles (SLNs) for controlled drug delivery - a re-view of the state of art. Eur J Pharm Biopharm 50: 161-177.
58. Oyewumi MO and Mumper RJ. (2002) Gadolinium loaded nanoparticles engineered from microemulsion templates. Drug Dev Ind Pharm 28: 317-328.
59. Oyewumi MO, Yokel RA, Jay M, et al. (2004) Compari-son of cell uptake, biodistribution and tumor reten-tion of folate coated and PEG- coated gadolinium nanoparticles in tumor bearing mice. J Control Re-lease 95: 613-626.
60. Partner BD, Johnston AB and Lenk TJ. (1987) Biomate-rial Surfaces. J. Biomed. Mat. Res. Appl. Biomat 21: 51-90.
61. Phillies GDJ. (1990) Quasielastic light scattering. Ana-lytical Chemistry: 1049A-1057A.
62. Popli PV and Singh KK. (2006) Development and evaluation of topical formulation containing solid lipid nanoparticles of vitamin A. AAPS PharmSciTech 7: Article 91.
63. Porter MR. (1994) Handbook of Surfactants, London: Chapman & Hill.
64. Reddy LH and Murthy RSR. (2005) Etoposide-loaded nanoparticles made from glyceride lipids: formula-tion, characterization, in vitro drug release, and sta-bility evaluation. AAPS PharmSciTech 6.
65. Santander-Ortega MJ, Jodar-Reyes AB, Csaba N, et al. (2006) Colloidal stability of Pluronic F68-coated PLGA nanoparticles: A variety of stabilization mechanisms. J Colloid interface Sci 302: 522-529.
66. Sarbak Z, Staczyk A and Kramer-wachowiak N. (2004) Characterization of surface properties of various fly ashes Powder Technology 145: 82-87.
67. Sarmento B, Ferriera D, Veiga F, et al. (2006) Charac-terization of insulin-loaded alginate nanoparticles produced by ionotropic pre-gelatin through DSC and FTIR studies. Carbohydr Polym 66: 1-7.
68. Scholer N, Olbrich C, Tabatt K, et al. (2001) Surfactant, but not the size of solid lipid nanoparticles (SLN) in-fluences viability and cytokine production of macro-phages. Int. J. Pharm 221: 57-67.
69. Scholes PD, Coombes AGA, Illum L, et al. (1999) Detec-tion and determination of surface level of poloxamer and PVA surfactant on biodegradable nanospheres using SSIMS and XPS. J Control Release 59: 261.
70. Schwarz C, Mehnert W, Lucks JS, et al. (1994) Solid lipid nanoparticles (SLN)for controlled drug delivery: I. Production, characterization and sterilization. J Con-trol Release 30: 83-96.
71. Seijo B, Fattal E, Roblot-treuple L, et al. (1990) Design of nanoparticles of less than 50 nm diameter: prepa- ration, characterization and drug loading. Int J Pharm 62: 1-7.
72. Sestier C, Da-silva MF, Sabolovic D, et al. (1998) Surface modification of superparamagnetic nanoparticles (Ferrofluid) studied with particle electrophoresis: ap-plication to the specific targeting of cells. Electropho-resis 19: 1220-1226.
73. Siekmann B and Westesen K. (1992) Submicron-sized parenteral carrier systems based on solid lipids. Pharm Pharmacol Lett 1: 123-126.
74. Siekmann B and Westesen K. (1994) Melt-homogenized solid lipid nanoparticles stabilized by the nonionic surfactants tylaxopol. Preparation and particle size determination. Pharm Pharmacol Lett 3: 194-197.
75. Srinath P and Diwan PV. (1994) Stealth Liposomes - An Overview. Indian J Pharmacol 26: 176-184.
76. Suresh G, Manjunath K, Venkateswarlu V, et al. (2007) Preparation, characterization and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles. AAPS PharmSciTech 8: Article 24.
77. Sznitowska M, Gajewska M, Janicki S, et al. (2001) Bioavailability of diazepam from aqueous-organic so-lution, submicron emulsion and solid lipid nanoparti-cles after rectal administration in rabbits. Eur J Pharm Biopharm 52: 159-163.
78. Triplett MD. (2004) Enabling solid lipid nanoparticle drug delivery technology by investigating improved production techniques.The ohio state University.
79. Trotta M, Debernardi F and Caputo O. (2003) Prepara-tion of solid lipid nanoparticles by solvent emulsifica-tion-diffusion technique. Int J Pharm 257: 153-160.
80. Trotta M, Gallarate M, Pattarino F, et al. (2001) Emusions containing partially water-missible solvents for the preparation of drug nanosuspensions. J Con-trol Release 76: 119-128.
81. Ugazio E, Cavalla R and Gasco MR. (2002) Incorporation of cyclosporin A in solid lipid nanoparticles (SLN). Int J Pharm 241: 341-344.
82. Venkateshwarlu V and Manjunath K. (2004) Prepara-tion, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release 95: 627-638.
83. Vigneshwaran N, Kathe AA, Varadarajan PV, et al. (2006) Biomimetics of silver nanoparticles by white rot fungus, phaenerochaete chrysosporium. Colloid Surf B Biointerfaces 53: 55-59.
84. Vivek K, Reddy H and Murthy RSR. (2007) Investiga-tions of the effect of the lipid matrix on drug entrap-ment, in vitro release, and physical stability of olan-zapine loaded solid lipid nanoparticles. AAPS Pharm-SciTech 8: E1-E9.
85. Vyas SP and Khar RK. (2002) Nanoparticles. In: Tar-geted and Controlled Drug Delivery. First ed. New Delhi: CBS Publishers and Distributors, 331-386.
86. Washington C. (1989) Evaluation of non-sink dialysis method for the measurement of drug release from colloids; effect of drug partition. Int J Pharm 56: 71-74.
87. Westesen K. (2000) Novel lipid based colloidal disper-sions as potential drug administration systems - ex-pectations and reality. Colloid Polym Sci 278: 0608-0618.
88. Westesen K, Bunjes H and Koch MJH. (1997) Physio-chemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sus-tained release potential. J Control Release 48: 223-236.
89. Westesen K, Siekmann B and Koch MHJ. (1993) Investi-gations on the physical state of lipid nanoparticles by synchrotron radiation X-ray diffraction. Int J Pharm 93: 189-199.
90. Williams, David B and Carter CB. (1996) Transmission electron microscopy: A text book of materials sci-ences, New York: Plenum Press.
91. Wissing SA, Kayser O and Muller RH. (2004) Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 56: 1257-1272.
92. Wong HL, Bendayan R, Rauth AM, et al. (2004) Devel-opment of solid lipid nanopartcles containing ioni-cally complexed chemotherapeutic drus and chemo-sensitizers. J Pharm Sci 93: 1993-2008.
93. Wong HL, Rauth AM, Bendayan R, et al. (2006) A new polymer- lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharm Res 23: 1574-1585.
94. Yang A, Yang L, Liu W, et al. (2007) Tumor necrosis fac-tor alpha blocking peptide based PEG-PLGA nanopar-ticles: Preparation in-vitro evaluation. Int J Pharm 331: 123-132.
95. Yang SC, Lu LF, Cai Y, et al. (1999) Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release 59: 299-307.
96. Yang SC, Zhu JB, Lu Y, et al. (1999) Body distribution of camptothecin solid lipid nanoparticles after oral ad-ministration. Pharm. Res 16: 751-757.
97. Zara GP, Bargoni A, Cavalli R, et al. (2002) Pharmacoki-netics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administra-tion to rats. J. Pharm. Sci 91: 1324-1333.
98. Zara GP, Cavalli R, Fundaro A, et al. (1999) Pharma-cokinetics of doxorubicin incorporated in solid lipid nanospheres (SLN). Pharmacol. Res. 40: 281-286.
99. Zhang D, Tan T and Gao L. (2006) Preparation of ori-donin-loaded solid lipid nanoparticles and studies on them in-vitro and in-vivo. Nanotechology 17: 5821-5828.
100. Zhang XJ, Xia Q, Ma QH, et al. (2005) Preparation of nanostructured lipid carriers loaded with retinoic acid by the high pressure homogenization method. Guocheng Gongcheng Xuebao/The Chinese Journal of Process Engineering 5: 54-57.
101. Zimmermann E, Muller RH and Madar K. (2000) Influ-ence of different parameters on reconstitution of ly-ophilized SLN. Int J Pharm 196: 211-213.
102. ZurMuhlen A, Schwarz C and Mehnert W. (1998) Solid Lipid Nanoparticle (SLN) for controlled drug delivery-Drug release and release mechanism. Eur J Pharm Biopharm 45: 149-155.